The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 937 GLP-1 Medications articles
Ozempic has transformed weight loss by silencing 'food noise' for many users, but now 'Ozempic personality' is sparking debate. A report highlights mental health complaints during treatment. Is this side effect real, or just hype?
Authorities in India have seized more than 260 suspected fake Mounjaro pens, uncovering a counterfeit operation sourcing peptides from Alibaba and selling them cheaply on IndiaMART. The primary accused lacked a pharmaceutical license and produced them at a private property. This incident underscores growing risks in the booming obesity drug market as Mounjaro becomes India's top-seller.
Musician Adele transformed her body in 2020, losing 100 pounds via exercise and a healthy diet amid rising anxiety after her 2019 divorce. Before Ozempic and Mounjaro gained popularity, she focused on building physical and mental strength. Her before-and-after photos and candid interviews reveal a powerful story of self-improvement.
The surge in GLP-1 weight-loss injections like semaglutide in India, fueled by prices dropping up to 90%, is alarming doctors amid rising cosmetic misuse by young women. Social media and wedding pressures are pushing unsupervised use, risking serious side effects. Experts stress these are prescription therapies for obesity, not quick fixes.
India's pharma giants are in a fierce race to develop generic GLP-1 drugs like semaglutide following its patent expiry, amid soaring obesity rates affecting nearly a third of adults. One executive dubbed it a 'bloodbath' as demand surges. Eli Lilly's CEO highlighted oral pills as a key solution to global supply shortages.
The launch of generic Semaglutide in India has rapidly captured 33% market share within just 10 days, according to CLSA's channel checks, primarily benefiting Torrent Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences. This surge has dented Eli Lilly's Mounjaro share from 61% to 56%. As generics make GLP-1 therapies more accessible, what does this mean for patients with type 2 diabetes and obesity?
In India, the GLP-1 rush is on—patients demand Ozempic or Mounjaro by name, generics slash costs to ₹1,290/month, fueled by Instagram and forums. But endocrinologists caution against indiscriminate use amid nausea, rebound weight, and serious risks. Inside the hype reshaping obesity treatment.
Popular drugs like semaglutide and tirzepatide are transforming weight loss for type 2 diabetes and obesity patients. But a new UNC study warns of hidden muscle loss that could impact strength and mobility. Here's what the research means for safe, healthy weight management.
Health Canada recently warned Canadians not to buy or use unauthorized injectable peptide drugs amid reports of adverse reactions. Yet CBC News effortlessly purchased three such products online from different sellers. Experts highlight serious risks and contrast them with regulated GLP-1 medications like Ozempic and Wegovy.
